Enanta Pharmaceuticals Inc (ENTA)

[willyw]

Gilead wins Chinese approval for Epclusa
https://www.fiercepharma.com/pharma-asia/gilead-wins-chinese-approval-for-epclusa-but-emerging-market-getting-crowded?mkt_tok=eyJpIjoiWkdZNFpHUTJZMlE1WmpkaCIsInQiOiJZTGNBT0xCcmtWZVpWVFhEY0wrbnYxc3M1eHdJcTNETXpkOUxcLytkU0dsQ0JWbEZOblhQSWhQYmhMWHRscEhYcU9HR0xsMzBiaHkxOEVUaUo1anVFRzRicjYxQUJEa21zRlJvRHlrRk5md0l6OGU0a0xoVlF3MFY5c3ptZGR5c1MifQ%3D%3D&mrkid=41425082

The question is, how soon will Maviret be approved for China?
Per the article; "Gilead then won approval for Sovaldi in September, the same time AbbVie got its ombitasvir and dasabuvir combo through."
(It's possible this is correct, but I keep thinking that sovaldi is a single drug which FDA approval preceeded the Abbvie 3D program by a year- article suggests 3D program was china approved before Harvoni, and then went straight to Epclusa approval-hmmmmm?!? ~W)

In any case, Epclusa approval (june 2016) preceded Mavyret US approval by over a year. It will be interesting to see how quickly Mavyret gains use in China.

FWIW, the 3D first gen Abbvie program was very effective in the Japanese market and China is comparable in both genetic makeup and in genotype pool. China could be a good market, and if the approval labeling were to be comparable to US and ex-US, it could offer the shortest pan-genotypic cure available to China's 10 million HCV+.

There are 7 more months left in the year. How soon will Maviret be approved in China?